We could not find any results for:
Make sure your spelling is correct or try broadening your search.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clini... CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities. Show more
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced...
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US...
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced...
- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration...
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.17 | -9.60451977401 | 1.77 | 1.7875 | 1.58 | 320676 | 1.67049663 | CS |
4 | -0.6 | -27.2727272727 | 2.2 | 2.3 | 1.58 | 645442 | 2.04566179 | CS |
12 | 0.07 | 4.57516339869 | 1.53 | 2.855 | 1.41 | 977055 | 2.26432989 | CS |
26 | 0.38 | 31.1475409836 | 1.22 | 2.855 | 1.04 | 612243 | 2.05999346 | CS |
52 | -0.02 | -1.23456790123 | 1.62 | 2.855 | 1.04 | 448496 | 1.92599206 | CS |
156 | -7.62 | -82.6464208243 | 9.22 | 10.05 | 1.04 | 1013229 | 2.96610052 | CS |
260 | -8.34 | -83.9034205231 | 9.94 | 15.44 | 1.04 | 821632 | 4.31064348 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions